CTLA4 and neoplasm: For instance, a GM-CSF-producing tumor cell vaccine combined with CTLA-4 blockade has important synergistic effects in reducing tumor size and increasing the antitumor immune response in a melanoma model (65) and in a prostate cancer model (66).